#EHA26 #EHA2026 Meeting of Leukemia research group at @EHA_Hematology | @doctorpemm @Daver_Leukemia @LeukDocJZ @sanamloghavi @NitinJainMD @TapKadia | @_MDEducation

A packed hall before our presentations in #EHA2026 on novel #AMLsm therapies where I am opening the session with our #KOMET007 study combination of #Ziftomenib with 7 3 & later my @YaleCancer colleague Nikolai Podoltsev will present Ph1 of Tuspetinib with aza-ven @YaleHematology

Wonderful Murali! If you get a chance it’s worth looking at the algorithm on Daraxonrasib by @allysonfelix and @MPishvaian and our software team. If you click on the boxes you get extra info such as dose, toxicity, management, graphs re PFS/OS. This is an early version and will evolve and grow over time as a living version 🎋🌳 We have listened to the community and our wonderful ‘rising stars’ such as @kor_shah and @allisonoconn We feel there is a need for a platform that provides the knowledge and nuance of a clinician with the best of software/website design and AI Thanks for your interest myopenmedicine.com/algorithm…

🧵 Post-BCMA Failure in RRMM: What should we do next? 🤔 A new multicenter USMIRC/US academic center real-world analysis provides practical insights into sequencing after BCMA-directed therapy failure. Here are the key takeaways for clinicians 👇 1️⃣ BCMA-directed therapy failure is becoming increasingly common, yet the optimal sequencing strategy remains undefined. 📌 This analysis integrates 3 multicenter real-world cohorts evaluating: 🔹 BCMA CAR-T 🔹 BCMA bispecific antibodies 🔹 Talquetamab (GPRC5D) #mmsm #myeloma #MedEd #Medtwitter #USMIRC @oncodaily @USMIRCNEWS @US_HMC @CurrentOncology @MedwatchKate @Larvol #المايلوما #سرطان_الدم

👉👉👉****Very important oral presentation #EHA26 #EHA2026 | John Mascarhenas | @EHA_Hematology AJX-101 ph1 results Type II JAK2i in patients with prior JAK2i | n=23 | #DiseaseModification with Both high SVR35 and TSS50 reductions in R/R setting| ********| @mpdrc #MPNSM

Not to brag….. but look whose 🥇 on the morphology leaderboard 🙋🏻‍♀️ 😎 at the cancilico booth at @EHA_Hematology #EHA2026 Scan the QR and test yourself

5 years from now or 50 years from now patients still want the same: Competent and empathetic physicians who are accessible when the need arises, and affordable care. We cannot wrap stuff with the word “innovation” when the changes in healthcare policies and priorities are reducing the development of clinical excellence, placing barriers to access, increasing cost of care, and accelerating burnout of experienced clinicians.

Thank you Kate. Incredibly strong week for AML which is close to my heart. Great to see such progress in haem onc. We need to learn from haem in solid tumours and to a lesser degree vice versa (IMO) Thank you @sanamloghavi @Dr_AmerZeidan @RahulBanerjeeMD @VincentRK and many more for all your guidance And some great 🎸🎸🎸🎸 Solid tumor friends some great work here @neerajaiims @amerseburger @montypal @drsarahsam @hoperugo @CharuAggarwalMD @StephenVLiu @PTarantinoMD

Swing by our poster PF565 on Gilteritinib Ven or Ivosidenib Ven based treatments of FLT3/IDH1m AML from 18.45 today🩸 @EHA_Hematology #eha2026 @VU_LT

#EHA2026 #EHA26 #leusm #AML GIMEMA AML2521 (Ph2): VEN-AZA for molecular failure in NPM1-mut AML as a bridge-to-transplant. Results are striking: • MRDneg 79% (median 2 cycles) • 85% bridged to HSCT, 70% MRDneg pre-SCT • 2-yr OS 95% / PFS 89% Key Takeaways 👇 Why VEN-AZA over the alternatives? 👉🏼 vs direct transplant: pre-HSCT MRD predicts relapse, so deepening first is rational — but a single-arm n=34 can’t separate true benefit from selection of favorable biology. 👉🏼 vs menin inhibitor: revumenib/zifto are now approved, but only for overt R/R disease (~21% CR/CRh); zero prospective data in the molecular-failure/bridge setting. Promising, practice-informing, hypothesis-generating; practice-changing? The MRD-directed menin ± VEN-AZA trial is the obvious next step. #leusm #AML #bmtsm #MRD

JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU ! Onward ! Great day for patients ! #HIF2 #oncology #labubu dailynews.ascopubs.org/do/li… blog.dana-farber.org/insight…

Just in time for EHA!

What are the most exciting abstracts in malignant hematology in #EHA2026 @EHA_Hematology that you look forward to ?

GU oncology community — this is your moment. @urologysummit #IUCS26 is now accepting abstracts in urological cancers, with travel grants, mini-oral opportunities, and e-posters available. A great platform to share real-world evidence, clinical research, and perspectives from diverse healthcare settings. Submit by July 10 👇 #UroOnc #GUOnc #CancerResearch #GlobalOncology Otra opción más fuerte, con mirada global: The future of GU oncology must include voices from every region. #IUCS26 is an opportunity to bring forward data, experience, and clinical questions from diverse healthcare systems — including LMIC and community-based settings. @gbanna74 @ravikanesvaran @amg120395 Akash Maniam @DrYukselUrun @yekeduz_emre Maria Barbu @nataliagandur @FabrizioDiCos Disha Khanna Michele Maffezzoli Giuseppe Neola @emanuele_crupi Submit your abstract by July 10. Let’s make the conversation broader, stronger, and more global. 👇